Nipro Corporation (JP:8086)
:8086
8086 Stock Chart & Stats
¥1502.50
-¥11.50(-0.77%)
At close: 4:00 PM EST
¥1502.50
-¥11.50(-0.77%)
Day’s Range― - ―
52-Week Range¥1,230.50 - ¥1,653.50
Previous CloseN/A
Volume329.50K
Average Volume (3M)504.50K
Market Cap
¥265.11B
Enterprise Value¥808.18B
Total Cash (Recent Filing)¥109.97B
Total Debt (Recent Filing)¥642.04B
Price to Earnings (P/E)5.6
Beta0.42
Next Earnings
May 12, 2026EPS Estimate
7.45Next Dividend Ex-DateN/A
Dividend Yield2.03%
Share Statistics
EPS (TTM)66.09
Shares Outstanding171,459,470
10 Day Avg. Volume391,050
30 Day Avg. Volume504,500
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)0.88
Price to Sales (P/S)0.34
P/FCF Ratio-27.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)89.99
Revenue Forecast (FY)¥676.80B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueNipro’s business relies on recurring sales of single-use consumables and B2B pharma packaging, creating predictable repeat demand from hospitals and manufacturers. This installed-base driven model supports steady revenue visibility, lowers customer acquisition needs, and enhances long-term cash predictability.
Consistent Revenue GrowthA near-double-digit revenue increase demonstrates the company’s ability to expand sales and gain share or pricing within its medical and pharma markets. Sustained top-line growth helps absorb fixed costs, supports investment in product lines, and underpins mid-term capacity and R&D plans.
Strong Operating Cash GenerationRobust operating cash flow relative to earnings indicates effective cash conversion from core operations. Persistent cash generation supports working capital for recurring sales, funds operating needs despite net income volatility, and provides a foundation for deleveraging or targeted reinvestment.
Bears Say
High LeverageElevated debt relative to equity constrains financial flexibility and raises interest obligations. In a capital-intensive medical supply business, high leverage limits ability to fund strategic M&A or capex without external financing and increases vulnerability to economic or demand slowdowns.
Negative Free Cash FlowPersistent negative free cash flow, even if improving, restricts the company’s ability to self-fund growth, dividends, or buybacks. Over the medium term this necessitates careful capex prioritization or external financing, which can amplify leverage and reduce strategic optionality.
Declining Net ProfitabilityA drop in net profit margin signals pressure on bottom-line performance despite stable gross margins. Sustained margin erosion can impair returns on equity, limit internal funding for R&D or expansion, and suggests cost or non-operating issues that must be addressed for long-term shareholder value.
Nipro News
8086 FAQ
What was Nipro Corporation’s price range in the past 12 months?
Nipro Corporation lowest stock price was ¥1230.50 and its highest was ¥1653.50 in the past 12 months.
What is Nipro Corporation’s market cap?
Nipro Corporation’s market cap is ¥265.11B.
When is Nipro Corporation’s upcoming earnings report date?
Nipro Corporation’s upcoming earnings report date is May 12, 2026 which is in 33 days.
How were Nipro Corporation’s earnings last quarter?
Nipro Corporation released its earnings results on Feb 09, 2026. The company reported ¥66.09 earnings per share for the quarter, beating the consensus estimate of ¥30.301 by ¥35.789.
Is Nipro Corporation overvalued?
According to Wall Street analysts Nipro Corporation’s price is currently Overvalued.
Does Nipro Corporation pay dividends?
Nipro Corporation pays a Semiannually dividend of ¥18 which represents an annual dividend yield of 2.03%. See more information on Nipro Corporation dividends here
What is Nipro Corporation’s EPS estimate?
Nipro Corporation’s EPS estimate is 7.45.
How many shares outstanding does Nipro Corporation have?
Nipro Corporation has 171,459,470 shares outstanding.
What happened to Nipro Corporation’s price movement after its last earnings report?
Nipro Corporation reported an EPS of ¥66.09 in its last earnings report, beating expectations of ¥30.301. Following the earnings report the stock price went up 0.242%.
Which hedge fund is a major shareholder of Nipro Corporation?
Currently, no hedge funds are holding shares in JP:8086
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nipro Corporation
Nipro Corporation (8086) is a global healthcare company headquartered in Japan, specializing in the development and manufacturing of medical devices, pharmaceuticals, and biotechnology. The company operates primarily in the areas of renal care, intravenous (IV) therapy, and blood transfusion, offering a wide range of products such as dialysis equipment, infusion systems, and various medical disposables. Nipro is committed to enhancing patient outcomes through innovative technologies and high-quality healthcare solutions.
Technical Analysis
Options Prices
Currently, No data available
---